Literature DB >> 25001975

Helicobacter pylori: perspectives and time trends.

Peter Malfertheiner1, Alexander Link1, Michael Selgrad1.   

Abstract

The discovery of Helicobacter pylori three decades ago is a modern medical success story. It markedly changed our understanding of the pathophysiology of gastroduodenal diseases and led to an improvement in the treatment of diseases related to H. pylori infection. Many of these diseases (such as ulcer disease and mucosal associated lymphoid tissue lymphoma) have become curable, and others (gastric cancer) might be preventable with the application of H. pylori eradication therapy. Since its discovery, H. pylori has also been identified as a trigger for some extragastric diseases. Promising results in this exciting field might have a clinical effect in the near future. This Timeline gives an overview of the success of clinical research on H. pylori to date and highlights some future trends in this area.

Entities:  

Mesh:

Year:  2014        PMID: 25001975     DOI: 10.1038/nrgastro.2014.99

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  38 in total

1.  Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls.

Authors:  Peter Malfertheiner
Journal:  United European Gastroenterol J       Date:  2015-10       Impact factor: 4.623

2.  Living biofouling-resistant membranes as a model for the beneficial use of engineered biofilms.

Authors:  Thammajun L Wood; Rajarshi Guha; Li Tang; Michael Geitner; Manish Kumar; Thomas K Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

Review 3.  Management of Helicobacter pylori Infection: What Should the Surgeon Know?

Authors:  Michael Selgrad; Peter Malfertheiner
Journal:  Visc Med       Date:  2017-06-16

4.  Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events.

Authors:  Lynne V McFarland; Ying Huang; Lin Wang; Peter Malfertheiner
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

Review 5.  What is the Relevance of Gastric Microbiota Beyond H. pylori?

Authors:  Kerstin Schütte; Peter Malfertheiner; Christian Schulz
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

6.  LINE-1 hypomethylation is not a common event in preneoplastic stages of gastric carcinogenesis.

Authors:  Juozas Kupcinskas; Ruta Steponaitiene; Cosima Langner; Giedre Smailyte; Jurgita Skieceviciene; Limas Kupcinskas; Peter Malfertheiner; Alexander Link
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

7.  Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").

Authors:  Eric A Engels; Ruth Parsons; Caroline Besson; Lindsay M Morton; Lindsey Enewold; Winnie Ricker; Elizabeth L Yanik; Hannah Arem; April A Austin; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-26       Impact factor: 4.254

Review 8.  Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases.

Authors:  Elizabeth Ma Rabelo-Gonçalves; Bruna M Roesler; José Mr Zeitune
Journal:  World J Hepatol       Date:  2015-12-28

Review 9.  The stomach in health and disease.

Authors:  R H Hunt; M Camilleri; S E Crowe; E M El-Omar; J G Fox; E J Kuipers; P Malfertheiner; K E L McColl; D M Pritchard; M Rugge; A Sonnenberg; K Sugano; J Tack
Journal:  Gut       Date:  2015-09-04       Impact factor: 23.059

10.  Diet Supplementation with Fish-Derived Extracts Suppresses Diabetes and Modulates Intestinal Microbiome in a Murine Model of Diet-Induced Obesity.

Authors:  Konstantinos Axarlis; Maria G Daskalaki; Sofia Michailidou; Nikolais Androulaki; Antiopi Tsoureki; Evangelia Mouchtaropoulou; Ourania Kolliniati; Ioanna Lapi; Eirini Dermitzaki; Maria Venihaki; Katerina Kousoulaki; Anagnostis Argiriou; Zouhir El Marsni; Christos Tsatsanis
Journal:  Mar Drugs       Date:  2021-05-11       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.